《《《《《《《《内容已删除》》》》》》》》》

大家在查：斯特履历文教 socialize 柄勺子 adjunct realize danger Tragedies Townhouse early days

昔单

昔单

昔单

1

The new study aimed to see if addition of the drug cetuximab , also known as Erbitux, would help patients even more.

最新的研究看出如果加用西妥昔单抗（又名爱比妥）可以明显增加这种手术切除的优势。

2

Moreover , infliximab use did not increase the proportion of patients who were able to taper their steroid dosages without relapse .

另外，使用英夫利昔单抗不会增加减少类固醇用量而不复发的患者比率。

3

Conclusion : Rituximab is a fine and phamacoeconomic choice for non-Hodgkin's lymphoma with satisfactory efficacy and safety .

结论：利妥昔单抗具有较好的疗效和安全性，也是治疗非霍奇金淋巴瘤较经济的方法。

4

Conclusions. Infliximab did not appear to interfere with disc herniation resorption oer a 6 -month period .

结论：英夫利昔单抗在 6个月的时间内似乎没有影响椎间盘疝出的再吸收。

5

It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody .

用抗 CD20 的单克隆抗体利妥昔单抗能够做到选择性的消耗 B 淋巴细胞。

6

Patients who have been treated with Rituxan and present or develop new neurological signs or symptoms should be evaluated for PML.

已服用利妥昔单抗的患者并存在或发生新的神经体征或症状的患者应评估是否患有 PML 。

8

Infliximab and its side -effect profile are discussed, along with other associated complications .

针对英利昔单抗的副作用和相关并发症进行了阐述。

10

11

Rituximab in combination with chemotherapy resulted in durable remission in a heavily pretreated subgroup.

利妥昔单抗联合化疗可使既往多次化疗的患者获得持续缓解。

12

Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B -cell lymphoma (DLBCL).

目的观察利妥昔单抗联合 CHOP 方案（R-CHOP ）治疗初治弥漫大 B 细胞型淋巴瘤的疗效以及毒副反应。

13

Conclusions : Infliximab was shown to be effective in the treatment of strictures in 3 patients .

结论：英夫利昔单抗在 3 名患者的肠腔狭窄治疗中有效果。

16

17

Two patients have died after being treated with Rituxan for systemic lupus erythematosus (SLE).

两位患者在服用利妥昔单抗治疗系统性红斑狼疮（SLE ）后死亡。

18

The use of bevacizumab (as well as cetuximab ) for maintenance remains unproven, however.

贝伐单抗（以及西妥昔单抗）对维持治疗仍无提高。

19

The adverse reaction was observed in 11 out of 100 patients during intravenous infusion of rituximab .

100 例患者中共有 11 例因静脉输注利妥昔单抗而发生输液不良反应。

20

No long-term toxicity potentially due to rituximab was observed .

未见利妥昔单抗的长期潜在毒性。

21

In these patients , severe hypomagnesaemia recurs rarely within 2 months from the start of cetuximab rechallenge.

这些病人中，西妥昔单抗二次给药两个月内复发严重低镁血症的极少。

24

We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients .

我们之前研究显示：KRAS 突变与 30 个 CRC 患者对西妥昔单抗耐药有关。

25

EMEA, the European Medicines Agency, has already restricted use of cetuximab and panitumumab to such patients .

欧洲药品局 EMEA 已经限制西妥昔单抗和帕尼单抗在这些患者使用。

26

Rituxan is being studied for other indications , and is prescribed off-label for other serious diseases and conditions such as SLE .

利妥昔单抗正在研究用于其他适应症，并用于说明书以外的其他严重疾病和情况如系统性红斑狼疮（SLE ）。

27

The sponsor estimates that approximately 10, 000 patients with SLE have been treated with Rituxan.

据估计约有 10,000 名患有 SLE 的患者曾用过利妥昔单抗。

28

based on favourable time-to-progression (TTP) and response -rate outcomes from the Bowel Oncology with Cetuximab Antibody (BOND) study .

基于有利的，从西妥昔单抗治疗肠肿瘤的研究得出，时间 -进程（TTP ）的和应答率的结果。

30

Results At 1 year , the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group .

结果：一年以后，利妥昔单抗组 C 肽水平的平均曲线下面积明显高于安慰机组。

热词推荐

大家在看